Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro

被引:83
作者
Kano, Y
Akutsu, M
Tsunoda, S
Ando, J
Matsui, J
Suzuki, K
Ikeda, T
Inoue, Y
Adachi, KI
机构
[1] TOCHIGI CANC CTR,DEPT SURG,UTSUNOMIYA,TOCHIGI 320,JAPAN
[2] TOCHIGI CANC CTR,DEPT LAB MED,UTSUNOMIYA,TOCHIGI 320,JAPAN
[3] KEIO UNIV,SCH MED,DEPT SURG,TOKYO 160,JAPAN
[4] KEIO UNIV,SCH MED,DEPT PLAST SURG,SHINJUKU KU,TOKYO 160,JAPAN
[5] NIPPON KAYAKU CO LTD,PHARMACEUT GRP,MED DATA CTR,KITA KU,TOKYO 115,JAPAN
关键词
paclitaxel; 5-fluorouracil; drug combination;
D O I
10.1038/bjc.1996.425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We assessed the cytotoxic interaction between paclitaxel nd 5-fluorouracil administered at various schedules against four human carcinoma cell lines, A549, MCF7, PA1 and WiDr. The cells were exposed simultaneously to paclitaxel and to 5-flourouracil for 24 h or sequentially to one drug for 24 h followed by the other for 24 h, after which they weer incubated in drug-free medium for 4 and 3 days respectively. In another experiment, the cells were exposed simultaneously to both agents for 5 days. Cell growth inhibition was determined by MTT reduction assay. The effects of drug combinations at IC80 were analyzed by the isobologram. The cytotoxic interaction of paclitaxel and 5-fluorouracil was definitely schedule dependent. Simultaneous exposure to paclitaxel and 5-fluorouracil for h showed mainly subadditive effects in A549, MCf7 and WiDr cell lines, whereas it showed additive effects in PA1 cells. Sequential exposure to paclitaxel followed by 5-fluorouracil showed additive effects in all cell lines. Sequential exposure to 5-fluorouracil followed by paclitaxel showed subadditive effects in A549, MCF7 and PA1 cells. Whereas it showed additive precedes 5-fluorouracil. Interestingly, the continuous (5-day) exposure to paclitaxel and 5-fluorouracil had additive effects in A549, PA1 and WiDr cells, indicating that the prolonged simultaneous administration of these agents may circumvent the antagonistic interaction produced by short-term simultaneous administration. These findings may be useful in clinical trials of combination chemotherapy with paclitaxel and 5-fluorouracil.
引用
收藏
页码:704 / 710
页数:7
相关论文
共 31 条
[1]   PACLITAXEL - WHAT SCHEDULE - WHAT DOSE [J].
ARBUCK, SG .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :233-236
[2]  
ASHELE C, 1992, CANCER RES, V52, P1855
[3]  
DONEHOWER RC, 1987, CANCER TREAT REP, V71, P1171
[4]   AN OVERVIEW OF EXPERIENCE WITH TAXOL (PACLITAXEL) IN THE USA [J].
DONEHOWER, RC ;
ROWINSKY, EK .
CANCER TREATMENT REVIEWS, 1993, 19 :63-78
[5]  
ELKORDY M, 1994, P AM SOC CLIN ONCOL, V13, P95
[6]  
ETTINGER DS, 1993, P AN M AM SOC CLIN, V12, P329
[7]  
GREM JL, 1987, CANCER TREAT REP, V71, P1179
[8]  
GUPTA RS, 1985, CANCER TREAT REP, V69, P515
[9]   PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].
HOLMES, FA ;
WALTERS, RS ;
THERIAULT, RL ;
FORMAN, AD ;
NEWTON, LK ;
RABER, MN ;
BUZDAR, AU ;
FRYE, DK ;
HORTOBAGYI, GN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805
[10]  
HOLMES FA, 1994, 8TH NCI EORTC S NEW, P197